Gene and cell therapies, which can be transformational for patients, are attractive investment targets for other reasons as well. “People are looking at what is probably a once in a lifetime opportunity in terms of new modalities for therapeutics via gene therapy, cell therapy, and the potential to completely change medicine,” said Mike Dombeck, chief operating officer at Arcellx, Inc., a clinical stage cell therapy company. It helps, too, that the FDA has created a welcoming regulatory environment for cell and gene therapies, and that early stage companies can turn into late stage companies rapidly.
Regarding the flow of investment funds into gene and cell therapies, Dombeck credited “good old fashioned NPV analyses,” or net...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
